Advertisement

Doklady Biochemistry and Biophysics

, Volume 469, Issue 1, pp 264–268 | Cite as

mRNA expression profile of mouse oligodendrocytes in inflammatory conditions

  • A. A. Kudriaeva
  • N. A. Khaustova
  • D. V. Maltseva
  • E. S. Kuzina
  • I. S. Glagoleva
  • E. A. Surina
  • V. D. Knorre
  • A. A. BelogurovJr.
  • A. G. Tonevitsky
  • A. G. Gabibov
Biochemistry, Biophysics, and Molecular Biology

Abstract

In this study, we performed transcriptome profiling of oligodendrocyte culture of mice treated with the remyelinating therapeutic agent benztropine in the presence and absence of interferon gamma (IFNγ). The results of this work are important for understanding the expression profile of oligodendrocytes under conditions of systemic inflammation in the central nervous system in multiple sclerosis as well as the mechanisms of cellular response to benztropine in light of its possible use for the treatment of multiple sclerosis.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Motl, R.W., McAuley, E., and Snook, E.M., Multiple Sclerosis, vol. 11, no. 4, pp. 459–463.Google Scholar
  2. 2.
    Deshmukh, V.A., Tardif, V., Lyssiotis, C.A., et al., Nature, 2013, vol. 502, no. 7471, pp. 327–332.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Oliveira-Ferrer, L., Rößler, K., Haustein, V., et al., Brit. J. Cancer, 2014, vol. 110, no. 3, pp. 753–763.PubMedCrossRefGoogle Scholar
  4. 4.
    Shi, L., Reid, L.H., Jones, W.D., et al., Nature Biotechnol., 2006, vol. 24, no. 9, pp. 1151–1161.CrossRefGoogle Scholar
  5. 5.
    Belogurov, A., Kudriaeva, A., Kuzina, E., et al., J. Biol. Chem., 2014, vol. 289, no. 25, pp. 17758–17766.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Huang, D.W., Sherman, B.T., and Lempicki, R.A., Nature Protocols, 2009, vol. 4, no. 1, pp. 44–57.CrossRefGoogle Scholar
  7. 7.
    Halonen, S.K., Woods, T., McInnerney, K., and Weiss, L.M., J. Neuroimmunol., 2006, vol. 175, no. 1, pp. 19–30.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Jahn, O., Tenzer, S., and Werner, H.B., Mol. Neurobiol., 2009, vol. 40, no. 1, pp. 55–72.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Taylor, C.M., Marta, C.B., Claycomb, R.J., et al., Proc. Nat. Acad. Sci. U. S. A., 2004, vol. 101, no. 13, pp. 4643–4648.CrossRefGoogle Scholar
  10. 10.
    Vanrobaeys, F., Van Coster, R., Dhondt, G., et al., J. Proteome Res., 2005, vol. 4, no. 6, pp. 2283–2293.PubMedCrossRefGoogle Scholar
  11. 11.
    Schultz, P., Lairson, L., Deshmukh, V., and Lyssiotis, C., Irm Llc and The Scripps Research Institute. U.S. Pat. (Appl.), 13/985.342.Google Scholar
  12. 12.
    Swiss, V.A., Nguyen, T., Dugas, J., et al., PLoS One, 2011, vol. 6, no. 4, p. e18088.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Wang, J. and Maldonado, M.A., Cell Mol. Immunol., 2006, vol. 3, no. 4, pp. 255–261.PubMedGoogle Scholar
  14. 14.
    Belogurov, A., Kuzina, E., Kudriaeva, A., et al., FASEB J., 2015, vol. 29, no. 5, pp. 1901–1913.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Maltseva, D.V., Khaustova, N.A., Fedotov, N.N., et al.., J. Clin. Bioinform., 2013, vol. 3, no. 1, p. 1.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2016

Authors and Affiliations

  • A. A. Kudriaeva
    • 1
  • N. A. Khaustova
    • 2
  • D. V. Maltseva
    • 2
  • E. S. Kuzina
    • 1
  • I. S. Glagoleva
    • 3
  • E. A. Surina
    • 1
  • V. D. Knorre
    • 1
  • A. A. BelogurovJr.
    • 1
    • 3
  • A. G. Tonevitsky
    • 2
  • A. G. Gabibov
    • 1
    • 3
    • 4
  1. 1.Shemyakin–Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia
  2. 2.BioKlinikum Scientific-Technical Center LLCMoscowRussia
  3. 3.Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal UniversityKazan, TatarstanRussia
  4. 4.Faculty of ChemistryMoscow State UniversityMoscowRussia

Personalised recommendations